Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far?

Driven by the clinical success of botulinum toxin serotype A (BoNT/A) and the need for improved chronic pain management, researchers attempted to develop re-designed botulinum toxin (BoNT)-based molecules as novel analgesics. Various recombinant protein expression strategies including retargeted bin...

Full description

Saved in:
Bibliographic Details
Published inCurrent opinion in pharmacology Vol. 78; p. 102476
Main Authors Matak, Ivica, Lacković, Zdravko
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2024
Subjects
Analgesics - therapeutic use
Animals
Botulinum Toxins, Type A - adverse effects
Botulinum Toxins, Type A - therapeutic use
Humans
Pain - drug therapy
Recombinant Proteins - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:Driven by the clinical success of botulinum toxin serotype A (BoNT/A) and the need for improved chronic pain management, researchers attempted to develop re-designed botulinum toxin (BoNT)-based molecules as novel analgesics. Various recombinant protein expression strategies including retargeted binding domains, and chimeric toxins combining different serotypes were tested to improve BoNT/A therapeutic safety margin and expand its efficacy. The aim of this review is to re-evaluate the current design strategies for recombinant BoNT-based molecules for pain treatment, compares their analgesic profile against the native BoNT/A, as well as to discuss the main strengths and potential weaknesses of reported approaches.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1471-4892
1471-4973
1471-4973
DOI:10.1016/j.coph.2024.102476